CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 11 No. 8
 

Research Helps Shed Light on Role of Apoptosis in Tumor Development and Growth

August 1, 1997

Many types of cells undergo apoptosis as part of the normal physiological process. An interruption in apoptosis is thought to be a primary cause of tumor growth. Two presentations concerning this subject were made at the 88th Annual Meeting of the American Association for Cancer Research (AACR).

In the first presentation, Stanley J. Korsmeyer, MD, of the Howard Hughes Medical Institute at Washington University School of Medicine in St. Louis, discussed a series of genes, B-cell lymphoma 2 (bcl-2), bax, bad, and abid, that regulate cell death. The bcl-2 protein has the novel function of blocking programmed cell death, extending the survival of cells normally destined to die. For example, mice that over-express bcl-2 progress to life-threatening lymphoma. According to Korsmeyer, bcl-2 does not act alone but duels with its counteracting twin, bax. When bax is in excess, cells execute the programed death command. However, when bcl-2 dominates, the process is interrupted and cells survive.

In studies of bcl-2-deficient mice, Dr. Korsmeyer found that the embryos developed normally. However, when the mice reached adulthood, bax predominated, leading to massive cell death of lymphocytes and the disappearance of lymphoid organs. In addition, the embryonic loss of kidney cells led to polycystic kidney disease, and the death of melanocytes caused hair hypopigmentation. When Dr. Korsmeyer studied bax-deficient mice, he found that bcl-2 predominated. These mice displayed cellular hyperplasia and aberrations in cell death during the development of the testes.

According to Dr. Korsmeyer, "bcl-2 represents an important control step in the common pathway of apoptosis present in all cells. Evidence indicating that it serves as a critical checkpoint includes its role in the generation of human disease, its importance in developmental cell death, and its selection as a site of interference by DNA viruses. Further study of the bcl-2 family holds the promise of improving our understanding of the pathway of programmed cell death and the aberrations in this process that result in malignancy."

A Second Study

In another study, Huachen Wei, MD, PhD, Associate Professor of Dermatology at the Mount Sinai School of Medicine in New York, and his colleagues evaluated methods of regulating apoptosis as a new approach to the understanding of ultraviolet-induced carcinogenesis. They hypothesized that apoptosis could be induced by stimulating the tumor suppressor gene p53 or by down-regulating the expression of the apoptosis suppressor gene bcl-2. The p53 gene is thought to suppress tumor growth through two mechanisms: by arresting cell growth at a specific phase in the cell cycle and by inducing apoptosis. Mutations in this gene are thought to be the most common genetic mutations in human cancers.

Using a cell line that expresses both p53 and bcl-2, the investigators found that ultraviolet B radiation (UVB) significantly induced the expression of p53 in a dose- and time-dependent manner. However, exposure to the equally cytotoxic dose of ultraviolet A radiation (UVA) produced no effects on p53 expression. On the other hand, UVA substantially down-regulated the expression of bcl-2, whereas exposure to the same level of UVB produced no change in the expression of bcl-2.

"Our results indicate that both UVA and UVB cause cell damage and induce apoptosis by completely separate mechanisms," said Dr. Wei. "Because mutations in p53 and over-expression of bcl-2 can result in human cancers, our findings suggest that ultraviolet radiation may provide a new approach for drug development," said Dr. Wei.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 52-Year-Old Man Presents With an Erythematous Lesion
Cesar Moran, MD , May 22, 2013

A 52-year-old man presented with an erythematous lesion in the axilla of unknown duration. Surgical excision was performed. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Preventing Exposure to Hazardous Drugs
  • Conflicts of Interest in Medicine: What About Ties to Payers?
  • Planning Treatment for Women With Recurrent Epithelial Ovarian Cancer
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy